Evaluating quality of life after kidney cancer treatments

February 19, 2018 by Anna Williams, Northwestern University

Patients with an advanced form of kidney cancer had similar quality of life outcomes taking a drug called cabozantinib as those who received the standard treatment, everolimus, according to a new Northwestern Medicine study. The findings were published in the Journal of Clinical Oncology.

Cabozantinib was approved by the FDA in 2016 for previously treated patients with advanced renal cell carcinoma, the most common in adults. The drug had been shown to improve key clinical outcomes in patients—including the response rate and progression-free survival—compared to everolimus. But it was not known what impact the drug had on patients' quality of .

"It is very common these days to see a new and exciting therapy come along. Often, those new therapies increase the proportion of people whose measurable tumors shrink or delay the average time it takes for the cancer to progress, but they do not necessarily lengthen life itself," said lead author David Cella, Ph.D., the Ralph Seal Paffenbarger Professor and chair of Medical Social Sciences. "In these cases, it becomes critically important to know if those clinical benefits are associated with better quality of life, or worse quality of life, compared to standard available therapy."

In the current study, the investigators assessed quality of life outcomes—such as side effects, disease-related symptoms and overall well-being—in patients with advanced renal cell carcinoma undergoing treatment with either cabozantinib or everolimus.

In the trial, 658 patients with advanced , who had all experienced disease progression despite previous treatment, were randomized to receive one of the two therapies.

Participants then completed a series of questionnaires at baseline and throughout the study about various measures of their quality of life.

The findings demonstrated that although side effects of the two treatments differed, there was no overall difference in quality of life between the two groups.

Still, even though patients who received cabozantinib did not necessarily live any better than those treated with everolimus, cabozantinib did extend overall time to deterioration—indicating that lived longer with a stable quality of life prior to seeing their cancer progress, when compared to everolimus.

"In this regard, the quality of life data support the superiority of cabozantinib over everolimus among people whose kidney cancer has progressed rapidly on prior ," Cella said.

Explore further: ASCO: Cabozantinib improves progression-free survival in RCC

More information: David Cella et al. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial, Journal of Clinical Oncology (2018). DOI: 10.1200/JCO.2017.75.2170

Related Stories

ASCO: Cabozantinib improves progression-free survival in RCC

January 5, 2016
(HealthDay)—For patients with advanced renal cell carcinoma, cabozantinib is associated with improved progression-free survival (PFS), with consistent improvement across all patient subgroups, according to a study scheduled ...

New drug improves outcome in treatment resistant kidney cancer

September 28, 2015
A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a ...

Results from Alliance CABOSUN trial lead to US FDA approval of extended indication

December 20, 2017
The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX (cabozantinib) tablets for the ...

Chemotherapy drug maintains quality of life despite side effects

November 6, 2017
Patients with advanced neuroendocrine tumors (NETs) reported similar health-related quality of life (HRQOL) during treatment with a recently approved chemotherapy drug as compared to patients receiving a placebo treatment, ...

Cabozantinib improves survival in patients with advanced kidney cancer

September 25, 2015
Vienna, Austria: Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that ...

Cabozantinib shows significant first-line activity for differentiated thyroid cancer

February 13, 2018
Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.